Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: Alfredo Nova who wrote (808)	11/5/1998 2:57:00 AM
From: FNS	Respond to of 965

Ciao, Alfredo: Re: < ...future IL-6 and IL-12 stories and great potential for remicade, I love it.> Looking forward to Remicade study results ... hope the stock holds ... nice run, ma spero che il prezzo vada piu' alto! (which means, if I said it correctly, that I wish that the price goes higher!) <<In the immunology arena, Phase III clinical results of Remicade (infliximab) in the treatment of rheumatoid arthritis will be presented at the American College of Rheumatology annual meeting in San Diego on November 12. Centocor plans to file a Biologics License Application with the Food and Drug Administration for this indication by the end of this year or early next year. >> buona fortuna tutti, FNS